Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Next Previous
X
Search
Trial Profile

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Dexchlorpheniramine; Diphenhydramine; Glatiramer acetate; Histamine H1 receptor antagonists; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Interferon beta; Interferon beta; Methylprednisolone; Paracetamol; Prednisolone; Ranitidine
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LemKids; na
  • Sponsors Sanofi Genzyme

    • Most Recent Events

    • 10 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
    • 19 Dec 2022 This trial has been Discontinued in Italy, according to European Clinical Trials Database record
    • 07 Apr 2021 Planned primary completion date changed from 1 Dec 2025 to 1 May 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top